The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?
作者信息
Younossi Zobair M
机构信息
Center for Liver Diseases, Department of Medicine Inova Fairfax Hospital Falls Church VA.
Betty and Guy Beatty Center for Integrated Research Inova Health System Falls Church VA.
出版信息
Clin Liver Dis (Hoboken). 2015 Dec 9;6(5):126-128. doi: 10.1002/cld.514. eCollection 2015 Nov.
Abstract
摘要
相似文献
1
The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?缩短丙型肝炎病毒治疗疗程的代价：这真的能节省成本吗？
Clin Liver Dis (Hoboken). 2015 Dec 9;6(5):126-128. doi: 10.1002/cld.514. eCollection 2015 Nov.
2
Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.直接作用抗病毒药物治疗丙型肝炎病毒 1 型感染具有成本效益。
Clin Gastroenterol Hepatol. 2017 Jun;15(6):827-837.e8. doi: 10.1016/j.cgh.2016.09.015. Epub 2016 Sep 17.
3
Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.通用泛基因型索磷布韦/维帕他韦与基于基因型的直接作用抗病毒药物治疗丙型肝炎的成本效益比较。
J Gastroenterol Hepatol. 2018 Dec;33(12):2029-2036. doi: 10.1111/jgh.14301. Epub 2018 Jun 25.
4
Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.系统评价：直接抗病毒药物治疗丙型肝炎2-6型的成本效益
Aliment Pharmacol Ther. 2017 Oct;46(8):711-721. doi: 10.1111/apt.14271. Epub 2017 Aug 24.
5
Availability and affordability of priority life-saving medicines for under-five children in health facilities of Tigray region, northern Ethiopia.提格雷地区（埃塞俄比亚北部）卫生机构中 5 岁以下儿童优先救命药品的可及性和可负担性。
BMC Pregnancy Childbirth. 2018 Nov 29;18(1):464. doi: 10.1186/s12884-018-2109-2.
6
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.新型丙型肝炎病毒治疗方案的成本效益分析。
Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152.
7
[The significance and place of HBsAg neutralization test in the diagnosis and algorithm of hepatitis B infection].[乙肝表面抗原中和试验在乙型肝炎感染诊断及诊疗流程中的意义与地位]
Mikrobiyol Bul. 2017 Apr;51(2):136-144. doi: 10.5578/mb.53835.
8
No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.并非一刀切——缩短丙型肝炎基因1型感染直接抗病毒药物的治疗疗程
J Viral Hepat. 2017 Oct;24(10):808-813. doi: 10.1111/jvh.12734. Epub 2017 Aug 9.
9
Cost-benefit analysis of hepatitis-B vaccination. A computerized decision model for Spain.乙型肝炎疫苗接种的成本效益分析。西班牙的计算机化决策模型。
Int J Technol Assess Health Care. 1991;7(3):379-402. doi: 10.1017/s0266462300005754.
10
Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation.肝移植后静脉注射和肌肉注射乙肝免疫球蛋白后，乙肝表面抗原抗体谷浓度和半衰期并无差异。
Liver Transpl. 2008 Apr;14(4):435-42. doi: 10.1002/lt.21343.
引用本文的文献
1
Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.泛基因型索磷布韦方案治疗中国慢性丙型肝炎病毒 1 型感染的成本效果分析。
Front Public Health. 2021 Dec 9;9:779215. doi: 10.3389/fpubh.2021.779215. eCollection 2021.
2
Shortening the duration of therapy for chronic hepatitis C infection.缩短慢性丙型肝炎感染的治疗时间。
Lancet Gastroenterol Hepatol. 2017 Nov;2(11):832-836. doi: 10.1016/S2468-1253(17)30053-5. Epub 2017 Aug 10.
本文引用的文献
1
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.丙型肝炎指南：美国肝病研究学会-美国感染病学会关于丙型肝炎病毒感染成人检测、管理及治疗的建议
Hepatology. 2015 Sep;62(3):932-54. doi: 10.1002/hep.27950. Epub 2015 Aug 4.
2
The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.慢性丙型肝炎患者从干扰素联合利巴韦林治疗到无干扰素和无利巴韦林治疗方案的历程：一项关于健康相关生活质量的研究。
Aliment Pharmacol Ther. 2015 Aug;42(3):286-95. doi: 10.1111/apt.13269. Epub 2015 Jun 9.
3
Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.雷迪帕韦/索磷布韦方案治疗慢性丙型肝炎感染：来自美国工作生产力经济模型的见解。
Hepatology. 2015 May;61(5):1471-8. doi: 10.1002/hep.27757. Epub 2015 Mar 23.
4
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.用 ledipasvir 和 sofosbuvir 治疗可改善患者报告的结局：来自 ION-1、-2 和-3 临床试验的结果。
Hepatology. 2015 Jun;61(6):1798-808. doi: 10.1002/hep.27724. Epub 2015 Mar 18.
5
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.全口服来迪派韦/索磷布韦方案治疗慢性丙型肝炎病毒1型感染患者的成本效益
Aliment Pharmacol Ther. 2015 Mar;41(6):544-63. doi: 10.1111/apt.13081. Epub 2015 Jan 26.
6
The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.新型抗病毒治疗方案对慢性丙型肝炎患者报告的结局及健康经济学的影响。
Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S186-96. doi: 10.1016/j.dld.2014.09.025. Epub 2014 Nov 10.
7
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.索磷布韦联合聚乙二醇干扰素/利巴韦林治疗慢性丙型肝炎病毒 1 型感染的成本效果分析。
Aliment Pharmacol Ther. 2014 Sep;40(6):657-75. doi: 10.1111/apt.12871. Epub 2014 Jul 28.
8
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.ABT-450/r-ombitasvir 和 dasabuvir 联合或不联合利巴韦林治疗 HCV。
N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.
9
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.来迪派韦索磷布韦片与索磷布韦联用治疗初治的 HCV 基因 1 型感染。
N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.
10
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗肝硬化合并丙型肝炎。
N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11.
Zotero 插件